Teicoplanin Prophylaxis for Total Hip or Knee Arthroplasty

Efficacy of Teicoplanin for the Prevention of Surgical Site Infections After Total Hip or Knee Arthroplasty: A Prospective, Open-Label Randomized Study

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00719056

Enrollment

616

Registered

2008-07-21

Start date

2004-08-31

Completion date

2007-12-31

Last updated

2008-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total Hip and Knee Arthroplasties

Keywords

teicoplanin, prophylaxis, arthroplasty, surgical site infections

Brief summary

This is a prospective, open-label, randomized clinical trial where patients were administered prophylaxis for total hip or knee arthroplasty either with teicoplanin or with other antibiotics. The study is aiming to evaluate any differences between these two different strategies of antimicrobial prophylaxis in the occurrence of surgical site infections

Detailed description

This is a prospective, open-label, randomized clinical trial where patients were administered prophylaxis for total hip or knee arthroplasty either with a single dose of teicoplanin or with multiple doses of other antibiotics according to the habits of the attending physicians aiming to evaluate any differences between these two different strategies of antimicrobial prophylaxis in the occurrence of surgical site infections

Interventions

DRUGTeicoplanin

The selected dose was 10mg/kg and it was given intravenously by a catheter inserted under aseptic conditions in a forearm vein within 15 minutes; it was diluted in one 5% glucose solution of a 50 ml final volume

DRUGβ-lactams or ciprofloxacin

Multiple doses for up to six consecutive days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients admitted for total hip arthroplasty * Patients admitted for total knee arthroplasty

Exclusion criteria

* Revision arthroplasty * History of any infection within the preceding two months * History of an operation in the same hip or knee for other causes * Known history of allergy to the studied drug * Pregnancy or lactation * Any antibiotic therapy in the week before operation.

Design outcomes

Primary

Measure	Time frame
To compare the efficacy of single dose teicoplanin compared with comparator agents in the prevention of surgical site infections after total hip or knee arthroplasty.	Two years

Secondary

Measure	Time frame
To compare the efficacy of single dose teicoplanin compared with comparator agents in the separate prevention of superficial or deep surgical site infections after total hip or knee arthroplasty.	Two years

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026